In the 18th edition of the BBVA Foundation Frontiers of Knowledge Awards, Carl June and Michel Sadelain have been honored in the category of Biology and Biomedicine for their groundbreaking advancements in cancer treatment. Their work with CAR-T cell therapies, which involve genetically modifying the patient's own T cells to combat cancer more effectively, has marked a significant revolution in the treatment of hematological tumors.

The award acknowledges the critical contributions of these researchers, who have been called the "fathers of CAR-T." This innovative therapeutic approach showcases how modifying the patient's immune cells can yield powerful results against cancers that were previously considered difficult to treat. Their collaboration has set a foundation for further developments in personalized medicine, underlining the importance of immunotherapy in oncology.

As this category of treatment continues to evolve, the recognition given by the BBVA Foundation is expected to spur increased interest and investment in CAR-T therapies. This could potentially lead to expanded clinical applications and even greater innovations in treating various forms of cancer, making this award not just a personal achievement for June and Sadelain but a pivotal moment for the future of cancer therapy.